This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Wendy Y. Craig, PhD
The Foundation for Blood Research Scarborough, Me

Andrew G. Bostom, MD, MS
USDA Human Nutrition Research Center on Aging Tufts New England Medical Center Boston, Mass

JAMA. 1995;274(15):1198.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In their article, Dr Ridker and colleagues¹ reported that there was no prospective association between lipoprotein(a) [Lp(a)] concentration and the risk of stroke. The authors summarized briefly the results of prior prospective studies of Lp(a) as a risk factor for coronary artery disease; however, certain points raised in that discussion require clarification. Namely, two studies that used the arbitrary nomenclature "apo (a)" for apolipoprotein (a) as opposed to "Lp(a)" were addressed separately. With one exception,² all studies to date have detected Lp(a) using immunoassays directed against apo(a). For example, Ridker et al¹ refer to "Lp(a)" and Wald et al³ in the article cited by Ridker et al refer to "apo(a)"; however, both groups used the Biopool ELISA (enzyme-linked immunosorbent assay). Thus, it is neither necessary nor appropriate to dichotomize studies based on differences in nomenclature. Therefore, among prior prospective studies of Lp(a) and . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?